Examkin

Soru

Zorluk: ZorPharmacologic Interventions

A 55-year-old man develops abrupt right-sided chest pain and dyspnea while recovering on the surgical ward. He underwent a partial colectomy for perforated diverticulitis 77 days ago. His postoperative recovery was complicated by severe sepsis and ischemic acute tubular necrosis, for which he currently requires hemodialysis every other day. Since the day of surgery, he has been receiving twice-daily subcutaneous injections of unfractionated heparin for deep vein thrombosis prophylaxis.

Current vital signs include a temperature of 37.2∘C37.2^\circ\text{C} (99.0∘F99.0^\circ\text{F}), blood pressure of 110/70 mm Hg110/70\text{ mm Hg}, heart rate of 118/min118/\text{min}, and respiratory rate of 24/min24/\text{min}. Pulse oximetry shows 92%92\% on 4 L/min4\text{ L/min} supplemental oxygen via nasal cannula.

A CT pulmonary angiogram confirms an acute segmental pulmonary embolism in the right lower lobe.

Today's laboratory results show:
Hemoglobin: 9.8 g/dL9.8\text{ g/dL}
Platelet count: 48,000/mm348,000/\text{mm}^3 (down from 260,000/mm3260,000/\text{mm}^3 on admission)
Blood urea nitrogen: 52 mg/dL52\text{ mg/dL}
Serum creatinine: 5.1 mg/dL5.1\text{ mg/dL}

The surgical team suspects heparin-induced thrombocytopenia (HIT). In addition to immediately discontinuing all heparin products, which of the following is the most appropriate pharmacologic intervention?

  1. A
    Initiate subcutaneous enoxaparin
  2. Initiate intravenous argatrobanCevap
  3. C
    Initiate subcutaneous fondaparinux
  4. D
    Initiate oral warfarin
  5. E
    Administer a platelet transfusion

Cevap

The most appropriate pharmacologic intervention is to initiate intravenous argatroban, as it provides necessary non-heparin anticoagulation and is safe to use in patients with severe renal impairment.
The correct answer is to initiate intravenous argatroban. This patient has developed a new pulmonary embolism and a significant drop in platelet count (greater than 50%) exactly 7 days after starting unfractionated heparin. This clinical picture is highly suspicious for heparin-induced thrombocytopenia (HIT) complicated by active thrombosis. The immediate management of HIT requires the cessation of all heparin-containing products and the rapid initiation of an alternative, non-heparin systemic anticoagulant to manage the hypercoagulable state. Because this patient has severe acute kidney injury requiring hemodialysis, the preferred agent is argatroban. Argatroban is a direct thrombin inhibitor that is hepatically metabolized, making it safe to use in patients with severe renal impairment without the need for significant dose adjustments.

Adım Adım Çözüm

1
Recognize the clinical presentation of heparin-induced thrombocytopenia (HIT).
The patient has a new pulmonary embolism and a platelet count drop of greater than 50% occurring 7 days after unfractionated heparin exposure, yielding a high 4T score for HIT.
Accurate diagnosis is required to guide the critical decision to stop all current heparin therapy.
2
Determine the immediate management goals for HIT complicated by thrombosis (HITT).
All heparin-containing products must be stopped, and a non-heparin systemic anticoagulant must be initiated immediately.
Despite profound thrombocytopenia, HIT is a severely prothrombotic state, and the new pulmonary embolism requires acute treatment.
3
Evaluate the patient's comorbidities to select the safest non-heparin anticoagulant.
The patient has severe acute kidney injury requiring hemodialysis. Argatroban is hepatically metabolized, whereas alternatives like fondaparinux are renally cleared.
Choosing a renally cleared drug in this patient would lead to toxic accumulation and severe bleeding.
4
Select the final optimal pharmacologic intervention.
Intravenous argatroban is chosen.
It fulfills the requirement for a non-heparin anticoagulant while remaining pharmacokinetically safe in the setting of end-stage renal disease or severe acute kidney injury.

Anahtar Kavram

In suspected heparin-induced thrombocytopenia (HIT), all heparin must be discontinued and a non-heparin anticoagulant started. Argatroban, a direct thrombin inhibitor, undergoes hepatic metabolism and is the preferred agent for patients with concurrent severe renal impairment.
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru